← 產業報告目錄
Filgrastim Biosimilars Market Size, Share & Trends Analysis Report By Application (Febrile Neutropenia, Genital Neutropenia, Idiopathic Neutropenia, and Others), By Distribution Channel (Online Pharmacy, Hospital Pharmacy, and Retail Pharmacy), Region And Segment Forecasts, 2023-2031
出版商 InsightAce Analytic產業別 Healthcare & Life Sciences出版日期 2026-02-02頁數 175報告編號 INSIGHTACE-dda3a09961
授權報價
| Single User PDF | $4,500 USD |
| Global Site License PDF | $9,500 USD |
報告摘要
The global Filgrastim Biosimilars Market is projected to advance at a compound annual growth rate of 8.5% throughout the 2025–2034 forecast period.
The Filgrastim Biosimilars sector involves key industry insights & findings from the report:
Governments around the world are promoting the use of biosimilars through various initiatives aimed at enhancing affordability and access. This domain has witnessed marked transformation owing to technological breakthroughs and shifting healthcare dynamics.
Market momentum is driven by growing need advanced solutions, favorable regulatory frameworks, and robust investment in research and development across major economies.
Segmental analysis reveals differentiated growth across product categories, applications, and geographical regions, with certain niches demonstrating above-average expansion potential.
From a regional perspective, mature markets in North America and Europe continue to hold marked shares, while the Asia-Pacific region is gaining momentum through accelerated economic development and growing investment in the sector.
Competition in this space is characterized by active product development, strategic collaborations, and geographic expansion among both global leaders and specialized niche players.
This comprehensive research study delivers granular insights into market sizing, trend analysis, competitive benchmarking, and forward-looking projections to support strategic decision-making for industry participants and investors.
目錄 Table of Contents
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Filgrastim Biosimilars Market Snapshot
Chapter 4. Global Filgrastim Biosimilars Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter's Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
4.9. Clinical Trial/Pipeline Analysis
Chapter 5. Market Segmentation 1: By Application Estimates & Trend Analysis
5.1. By Application & Market Share, 2024 & 2034
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Application:
5.2.1. Febrile neutropenia
5.2.2. Genital neutropenia
5.2.3. Idiopathic neutropenia
5.2.4. Others
Chapter 6. Market Segmentation 2: By Distribution Channel Estimates & Trend Analysis
6.1. By Distribution Channel & Market Share, 2024 & 2034
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following By Distribution Channel:
6.2.1. Hospital Pharmacy
6.2.2. Retail Pharmacy
6.2.3. Online Pharmacy
Chapter 7. Filgrastim Biosimilars Market Segmentation 3: Regional Estimates & Trend Analysis
7.1. North America
7.1.1. North America Filgrastim Biosimilars Market revenue (US$ Million) estimates and forecasts By Application, 2021 - 2034
7.1.2. North America Filgrastim Biosimilars Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2021 - 2034
7.1.3. North America Filgrastim Biosimilars Market revenue (US$ Million) estimates and forecasts by country, 2021 - 2034
7.2. Europe
7.2.1. Europe Filgrastim Biosimilars Market revenue (US$ Million) By Application, 2021 - 2034
7.2.2. Europe Filgrastim Biosimilars Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2021 - 2034
7.2.3. Europe Filgrastim Biosimilars Market revenue (US$ Million) by country, 2021 - 2034
7.3. Asia Pacific
7.3.1. Asia Pacific Filgrastim Biosimilars Market revenue (US$ Million) By Application, 2021 - 2034
7.3.2. Asia Pacific Filgrastim Biosimilars Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2021 - 2034
7.3.3. Asia Pacific Filgrastim Biosimilars Market revenue (US$ Million) by country, 2021 - 2034
7.4. Latin America
7.4.1. Latin America Filgrastim Biosimilars Market revenue (US$ Million) By Application, (US$ Million)
7.4.2. Latin America Filgrastim Biosimilars Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2021 - 2034
7.4.3. Latin America Filgrastim Biosimilars Market revenue (US$ Million) by country, (US$ Million) 2021 - 2034
7.5. Middle East & Africa
7.5.1. Middle East & Africa Filgrastim Biosimilars Market revenue (US$ Million) By Application, (US$ Million)
7.5.2. Middle East & Africa Filgrastim Biosimilars Market revenue (US$ Million) estimates and forecasts By Distribution Channel, 2021 - 2034
7.5.3. Middle East & Africa Filgrastim Biosimilars Market revenue (US$ Million) by country, (US$ Million) 2021 - 2034
Chapter 8. Competitive Landscape
8.1. Major Mergers and Acquisitions/Strategic Alliances
8.2. Company Profiles
8.2.1. Aryogen Biopharma
8.2.2. Cadila Pharmaceutical
8.2.3. Claris Life Sciences
8.2.4. Dr Reddy's Laboratories
8.2.5. Intas Biopharmaceuticals
8.2.6. Adello Biologics
8.2.7. Hospira(Pfizer)
8.2.9. Gennova Biopharmaceuticals
8.2.10. Teva Pharmaceutical Industries
8.2.11. Sandoz
8.2.12. Other Prominent Players
量子訊息有限公司為 InsightAce Analytic 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們